Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$202 Mln
Revenue (TTM)
$115 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
EV/EBITDA
2.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$4.8
EPS
$-1
Face value
--
Shares outstanding
69,126,173
CFO
$187.92 Mln
EBITDA
$156.56 Mln
Net Profit
$89.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
OraSure Technologies (OSUR)
| 27.3 | -2.2 | 27.3 | -7.2 | -20.2 | -23.4 | -8.1 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
OraSure Technologies (OSUR)
| -33.0 | -55.7 | 70.1 | -44.5 | -17.9 | 31.8 | -31.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
OraSure Technologies (OSUR)
|
3.1 | 201.9 | 115.0 | -68.7 | -61.2 | -18.3 | -- | 0.6 |
| 7.9 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,510.1 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10 | 1.0 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,549.6 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.0 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,964.3 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.9 | 9.0 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,716.9 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.5 | 2.6 |
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick... Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania. Address: 220 East First Street, Bethlehem, PA, United States, 18015 Read more
President, CEO & Director
Ms. Carrie Eglinton Manner
President, CEO & Director
Ms. Carrie Eglinton Manner
Headquarters
Bethlehem, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of OraSure Technologies Inc (OSUR) is $3.08 (NASDAQ) as of 02-Apr-2026 16:26 EDT. OraSure Technologies Inc (OSUR) has given a return of -20.15% in the last 3 years.
Since, TTM earnings of OraSure Technologies Inc (OSUR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.52
|
0.51
|
|
2024
|
-13.78
|
0.65
|
|
2023
|
11.46
|
1.43
|
|
2022
|
-20.61
|
0.97
|
|
2021
|
-27.22
|
1.65
|
The 52-week high and low of OraSure Technologies Inc (OSUR) are Rs 3.82 and Rs 2.08 as of 05-Apr-2026.
OraSure Technologies Inc (OSUR) has a market capitalisation of $ 202 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in OraSure Technologies Inc (OSUR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.